Research ArticleBasic Science Investigations

A Modular Labeling Strategy for In Vivo PET and Near-Infrared Fluorescence Imaging of Nanoparticle Tumor Targeting

Carlos Pérez-Medina, Dalya Abdel-Atti, Yachao Zhang, Valerie A. Longo, Chrisopher P. Irwin, Tina Binderup, Jesús Ruiz-Cabello, Zahi A. Fayad, Jason S. Lewis, Willem J.M. Mulder and Thomas Reiner
Journal of Nuclear Medicine October 2014, 55 (10) 1706-1711; DOI: https://doi.org/10.2967/jnumed.114.141861

Article Figures & Data

Figures

  • FIGURE 1.
    FIGURE 1.

    (A and B) Strategies for labeling of liposomes with 89Zr by click labeling (A) and surface chelation (B). (C) Lipid composition of liposomes used in present work. PBS = phosphate-buffered saline.

  • FIGURE 2.
    FIGURE 2.

    (A and B) Size-exclusion chromatograms showing radioactive traces of 89Zr-CLL and 89Zr-9 (A) and 89Zr-SCL and 89Zr-oxalate (B). (C) In vitro serum stability of 89Zr-CLL and 89Zr-SCL.

  • FIGURE 3.
    FIGURE 3.

    (A) Pharmacokinetics of 89Zr-SCL and 89Zr-CLL (n = 3). (B) Radioactivity distribution in selected tissues of 89Zr-SCL and 89Zr-CLL (n ≥ 3). (C) PET/CT imaging of 89Zr-SCL: CT only (left), PET/CT fusion (middle), and 3-dimensional rendering of PET/CT fusion (right) at 24 h after injection.

  • FIGURE 4.
    FIGURE 4.

    (A) Schematic of dual-labeled liposome DiIC@89Zr-SCL. (B) Whole-body NIR fluorescence imaging (excitation wavelength = 650 nm/emission wavelength = 670 nm) (left) and 3-dimensional rendering of PET/CT fusion image (right) of same animal at 24 h after administration of DiIC@89Zr-SCL. (C) Tumor sections showing autoradiography (top) and confocal microscopy at 670 nm (bottom). (D) Comparison of NIR fluorescence (NIRF) and PET quantification measurements in tumor and skin areas (skin-to-muscle ratio for PET; n = 3).

Additional Files

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords